Genmab — Februar 2019
-
Following on from the encouraging preliminary activity seen in the cervical cancer cohort in this
study, InnovaTV 204 (NCT03438396) is an ongoing
phase 2 study evaluating the activity, safety, and
tolerability of tisotumab vedotin monotherapy in patients
with recurrent or metastatic cervical cancer that had
progressed during or after treatment with standard firstline therapy. -
-
@bulder 10.26. Kunne man tænke sig at at Novos tek. ang. Pilleform kunne overføres til Dara og Tiso qua deres samarbejde i kulissen. Det kunne jo være at der var et eller andet i gang som ikke kommer frem før der er sat noget i gang. ??. Når sc Dara kommer er det jo fremragende, -men hvis de kunne lave en oral version. Game over.
-
Lidt om Morphosys dommen
https://www.lw.com/mediaCoverage/litigators-of-the-week-latham-IP-litigators-kill-patent-challenge
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind